Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Persistent Atrial Fibrillation: a Prospective Multi-centre Randomized Controlled Clinical Study
Latest Information Update: 15 Dec 2023
Price :
$35 *
At a glance
- Drugs Flecainide (Primary) ; Propafenone (Primary) ; Sotalol (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms POWDER-AF2
- 01 Nov 2023 Results (n=200) assessing the benefit of continuing previously ineffective class 1C or 3 antiarrhythmic drug therapy (ADT) in the setting of a standardized PVI-only ablation strategy, published in the Circulation: Arrhythmia and Electrophysiology.
- 08 Jul 2022 Status changed from active, no longer recruiting to completed.
- 04 Jun 2021 Planned End Date changed from 31 Mar 2021 to 30 Jun 2022.